<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2213">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04409834</url>
  </required_header>
  <id_info>
    <org_study_id>CCCTN/TIMI COVID-PACT</org_study_id>
    <nct_id>NCT04409834</nct_id>
  </id_info>
  <brief_title>Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial</brief_title>
  <acronym>COVID-PACT</acronym>
  <official_title>A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The TIMI Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The TIMI Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in
      critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the
      efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of
      antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic
      events.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint: Venous or arterial thrombotic events</measure>
    <time_frame>28 days or until hospital discharge, whichever earlier</time_frame>
    <description>Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia, or clinically silent DVT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key secondary endpoint: Clinically evident venous or arterial thrombotic events</measure>
    <time_frame>28 days or until hospital discharge, whichever earlier</time_frame>
    <description>Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>COVID-19</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Arterial Thrombosis</condition>
  <arm_group>
    <arm_group_label>Full-dose anticoagulation + antiplatelet therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Full-dose anticoagulation: Unfractionated heparin IV continuous targeting aPTT of 1.5-2.5X control, or Enoxaparin 1 mg/kg SC Q12h
• Anti-platelet therapy: Clopidogrel 300 mg PO x1, followed by clopidogrel 75 mg PO QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Full-dose anticoagulation + no antiplatelet therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Full-dose anticoagulation: Unfractionated heparin IV continuous targeting aPTT of 1.5-2.5X control, or Enoxaparin 1 mg/kg SC Q12h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylactic anticoagulation + antiplatelet therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Standard prophylactic anticoagulation: Enoxaparin 40 mg SC QD or Unfractionated heparin 5,000 IU SC TID
• Antiplatelet therapy: Clopidogrel 300 mg PO x1, followed by clopidogrel 75 mg PO QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylactic anticoagulation + no antiplatelet therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• Standard prophylactic anticoagulation: Enoxaparin 40 mg SC QD or Unfractionated heparin 5,000 IU SC TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated Heparin IV</intervention_name>
    <description>Unfractionated heparin IV targeting an aPTT of 1.5-2.5 times the control</description>
    <arm_group_label>Full-dose anticoagulation + antiplatelet therapy</arm_group_label>
    <arm_group_label>Full-dose anticoagulation + no antiplatelet therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 1 mg/kg</intervention_name>
    <description>Enoxaparin 1 mg/kg SC Q12h</description>
    <arm_group_label>Full-dose anticoagulation + antiplatelet therapy</arm_group_label>
    <arm_group_label>Full-dose anticoagulation + no antiplatelet therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 300 mg PO x1, then clopidogrel 75 mg PO QD</description>
    <arm_group_label>Full-dose anticoagulation + antiplatelet therapy</arm_group_label>
    <arm_group_label>Prophylactic anticoagulation + antiplatelet therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated heparin SC</intervention_name>
    <description>Unfractionated heparin 5,000 IU SC TID</description>
    <arm_group_label>Prophylactic anticoagulation + antiplatelet therapy</arm_group_label>
    <arm_group_label>Prophylactic anticoagulation + no antiplatelet therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 40 Mg/0.4 mL Injectable Solution</intervention_name>
    <description>Enoxaparin 40 mg SC QD</description>
    <arm_group_label>Prophylactic anticoagulation + antiplatelet therapy</arm_group_label>
    <arm_group_label>Prophylactic anticoagulation + no antiplatelet therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years (male or female)

          2. Acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)

          3. Currently admitted to an intensive care unit (ICU)

        Key Exclusion Criteria:

          1. Ongoing (&gt;48 hours) or planned full-dose (therapeutic) anticoagulation for any
             indication

          2. Ongoing or planned treatment with dual antiplatelet therapy

          3. Contraindication to antithrombotic therapy or high risk of bleeding due to conditions
             including, but not limited to, any of the following:

               1. History of intracranial hemorrhage, known CNS tumor or CNS vascular abnormality

               2. Active or recent major bleeding within the past 30 days with untreated source

               3. Platelet count &lt;70,000 or known functional platelet disorder

               4. Fibrinogen &lt;200 mg/dL

               5. International normalized ratio (INR) &gt;1.9

          4. History of heparin-induced thrombocytopenia

          5. Ischemic stroke within the past 2 weeks

        Patients who meet the following criterion are excluded from the second randomization
        (antiplatelet therapy vs. no antiplatelet therapy):

        1. Ongoing or planned antiplatelet therapy, including aspirin monotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc S Sabatine, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>TIMI Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A Morrow, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>TIMI Study Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivian Baird-Zars</last_name>
    <phone>800-385-4444</phone>
    <email>vbaird-zars@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>August 16, 2020</last_update_submitted>
  <last_update_submitted_qc>August 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

